Latest News
& Press Releases

Adecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target to the existing agreement, with an option for a second.

After a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.

CSL will co-develop and co-promote Alentis Therapeutics’ anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

All signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study. Data from two Phase 3 studies of systemic lupus are expected by the end of the year.

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.

Not a month after reports of three deaths in autoimmune trials for Novartis’ CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

CEO Matt Gline is juggling Roivant Sciences’ first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.

The FDA has taken important steps through Operation TrialBlazer and stronger scrutiny of foreign clinical data, but more must be done to make the United States more competitive in attracting clinical trials as China’s capabilities rise.

A surge of consolidation, rising appetite for specialized manufacturing and a shift toward decentralized trials is reshaping Switzerland’s life sciences landscape. From peptide producers to organoid CROs, service providers are scaling and diversifying as global sponsors turn to Swiss hubs for talent, innovation and regulatory strength.

Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher’s proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform’s entry point, are planned for Q4 2026. Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine dissolvable tablet for telehealth in Q1 2027. Rare pediatric NDA with voucher potential. Orphan drug and rare pediatric disease designation applications are planned for October 2026, with a pre-IND meeting in Q1 2027 and an NDA submission targeted for Q4 2028. Approval could earn a priority review voucher; recent vouchers have sold for US$100–155 million. Pipeline expansion into underserved markets. PharmaTher is evaluating three underserved markets where small-batch production is an advantage: ultra-rare diseases with no FDA-approved treatment, psychedelic medicines for clinical trials and special access, and discontinued medicines that mass manufacturing no longer serves. National emergency network. Every CraftMake™ placement can become a node that prints medical countermeasures on demand. PharmaTher plans to pursue readiness contracts with U.S. and Canadian agencies. New website and brand. PharmaTher has launched its new corporate website at PharmaTher.com, and PERSONALIZ3D™ is now M3DICINES™ (M3DICINES.com).

Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma

VIVI Cap Smart transforms injectable medication protection into a connected health-data layer, enabling patients, caregivers and digital-health platforms to capture medication-use, temperature and adherence signals.

• Vial’s IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody • Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M) dosing • Phase 1b study will evaluate safety, tolerability, pharmacokinetics, and FeNO-based proof-of-mechanism in patients with mild-to-moderate asthma • Interim Phase 1b data readout expected in H1 2027